通过vidofludimus对Nurr1调制的结构和机制分析使得结构导向的连接体设计成为可能
Úrsula López-García1, Jan Vietor1, Julian A Marschner1
1Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
Communications chemistry
|May 21, 2025
概括
这项研究揭示了合成配体如何激活神经保护蛋白Nurr1 (NR4A2),这对于治疗帕金森氏症等神经退行性疾病至关重要. 了解Nurr1激活为开发新药铺平了道路.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与核受体相关的1 (Nurr1,NR4A2) 是一个关键的神经保护性转录因子,与帕金森病,阿尔茨海默病和多发性硬化症有关.
- 通过连接体对Nurr1活性进行药理调节是一种有前途的治疗策略,但其激活机制尚不清楚.
研究的目的:
- 阐明合成Nurr1激活剂的分子机制和结合部位.
- 为了使新的,强大的Nurr1激动剂的结构导向设计能够用于治疗开发.
主要方法:
- 用定位突变和分子动力学模拟来描述Nurr1-连接物相互作用.
- 使用Vidofludimus作为模型合成激活剂来探测Nurr1激活通路.
主要成果:
- 维多弗鲁迪姆斯与Nurr1的全质表面口袋结合,其中包括1,5,7和8的螺旋环.
- 由vidofludimus激活Nurr1,涉及二聚体解离和核心调节器释放.
- 由结构引导的优化导致了一种具有显著增强功效和结合亲和力的新型Nurr1激动剂.
结论:
- 这项研究提供了对激动剂合成Nurr1激活的第一个结构和分子见解.
- 这些发现为合理的药物设计奠定了基础,针对神经退行性疾病的Nurr1.
相关概念视频
Structure-Activity Relationships and Drug Design
474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474
Ligand Binding Sites
12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Covalently Linked Protein Regulators
6.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.7K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K


